Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women

Christine B Ambrosone; Gary Zirpoli; Chi-Chen Hong; Song Yao; Melissa A Troester; Elisa V Bandera; Pepper Schedin; Traci N Bethea; Virginia Borges; Song-Yi Park; Dhyan Chandra; Lynn Rosenberg; Laurence N Kolonel; Andrew F Olshan; Julie R Palmer

doi:10.1093/jnci/djv172

Back

Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women

Journal article

Open access

Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women

Christine B Ambrosone, Gary Zirpoli, Chi-Chen Hong, Song Yao, Melissa A Troester, Elisa V Bandera, Pepper Schedin, Traci N Bethea, Virginia Borges, Song-Yi Park, …

JNCI : Journal of the National Cancer Institute, Vol.107(9), p.1

09/2015

DOI: https://doi.org/10.1093/jnci/djv172

PMCID: PMC4836800

PMID: 26085483

Abstract

Adolescent

Adult

African Americans - statistics & numerical data

Age Factors

Aged

Breast Feeding

Breast Neoplasms - chemistry

Breast Neoplasms - epidemiology

Child

Confounding Factors (Epidemiology)

Female

Humans

Logistic Models

Menarche

Menopause

Middle Aged

Odds Ratio

Parity

Pregnancy

Receptors, Estrogen - analysis

Reproductive History

Surveys and Questionnaires

United States - epidemiology

Menarche is a critical time point for diverging fates of mammary cells of origin. African American women have young age at menarche, which could be associated with their high rates of estrogen receptor-negative (ER-) breast cancer. In the AMBER Consortium, using harmonized data from 4426 African American women with breast cancer and 17 474 controls, we used polytomous logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for ages at menarche and first live birth (FLB), and the interval between, in relation to ER+ and ER- breast cancer. All statistical tests were two-sided. Risk of ER- breast cancer was reduced with later age at menarche among both parous and nulliparous women (≥15 vs <11 years OR = 0.62, 95% CI = 0.48 to 0.81 and OR = 0.56, 95% CI = 0.29 to 1.10, respectively), with no effect of age at FLB. For ER+ breast cancer, the inverse association was weaker among nulliparous women. While longer intervals between menarche and FLB were associated with increased risk of ER+ breast cancer in a dose-response fashion (OR for 20 year interval = 1.39, 95% CI = 1.08 to 1.79, P trend = .003), ER- risk was only increased for intervals up to 14 years and not beyond (P trend = .33). While ER- breast cancer risk was markedly reduced in women with a late age at menarche, there was not a clear pattern of increased risk with longer interval between menarche and FLB, as was observed for ER+ breast cancer. These findings indicate that etiologic pathways involving adolescence and pregnancy may differ for ER- and ER+ breast cancer.

Files and links (1)

url

https://doi.org/10.1093/jnci/djv172View

Version of Record (VoR) Open

Metrics

12 Record Views

35 Times Cited - Web of Science

See more details

Details

Title: Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women
Creators: Christine B Ambrosone - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK). christine.ambrosone@roswellpark.org
Gary Zirpoli - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Chi-Chen Hong - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Song Yao - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Melissa A Troester - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Elisa V Bandera - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Pepper Schedin - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Traci N Bethea - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Virginia Borges - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Song-Yi Park - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Dhyan Chandra - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Lynn Rosenberg - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Laurence N Kolonel - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Andrew F Olshan - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Julie R Palmer - Roswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK)
Publication Details: JNCI : Journal of the National Cancer Institute, Vol.107(9), p.1
Date published: 09/2015
Grant note: P50 CA58223 / NCI NIH HHS U01 ESO19472 / PHS HHS R01 CA058420 / NCI NIH HHS R01 CA169175 / NCI NIH HHS R01 CA185623 / NCI NIH HHS P30 ES010126 / NIEHS NIH HHS R01 CA54281 / NCI NIH HHS UM1 CA164973 / NCI NIH HHS UM1 CA164974 / NCI NIH HHS P50 CA058223 / NCI NIH HHS R01 CA100598 / NCI NIH HHS P01 CA151135 / NCI NIH HHS
Academic Unit: Cancer Epidemiology and Health Outcomes
Language: English
Resource Type: Journal article
Identifiers: 991031665030904646